Novartis Ag Adr Stock Today
| NVS Stock | USD 105.77 0.90 0.86% |
Performance0 of 100
| Odds Of DistressLess than 5
|
Novartis is selling for under 105.77 as of the 30th of November 2024; that is 0.86% increase since the beginning of the trading day. The stock's lowest day price was 104.86. Novartis has under 5 % chance of experiencing financial distress over the next 2 years, but has generated negative returns over the last 90 days. Note, on May 19, 2024, Senator Sheldon Whitehouse of US Senate acquired under $15k worth of Novartis AG ADR's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of November 1991 | Category Healthcare | Classification Health Care |
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 2 B outstanding shares of which 4.79 M shares are now shorted by investors with about 3.83 days to cover. More on Novartis AG ADR
Moving together with Novartis Stock
| 0.82 | HLN | Haleon plc | PairCorr |
| 0.91 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.89 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.84 | ANRO | Alto Neuroscience, | PairCorr |
| 0.8 | SHG | Shinhan Financial | PairCorr |
Moving against Novartis Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Novartis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Richard Saynor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Compulsion, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNovartis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Novartis' financial leverage. It provides some insight into what part of Novartis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis AG ADR (NVS) is traded on New York Stock Exchange in USA. It is located in Lichtstrasse 35, Basel, Switzerland, 4056 and employs 76,057 people. Novartis is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 211.46 B. Novartis AG ADR runs under Pharmaceuticals sector within Health Care industry. The entity has 2 B outstanding shares of which 4.79 M shares are now shorted by investors with about 3.83 days to cover.
Novartis AG ADR has about 4.64 B in cash with 14.46 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.84.
Check Novartis Probability Of Bankruptcy
Ownership AllocationNovartis AG ADR maintains a total of 2 Billion outstanding shares. Roughly 93.26 % of Novartis outstanding shares are held by general public with 6.74 % by institutional investors. Please note that on May 19, 2024, Senator Sheldon Whitehouse of US Senate acquired under $15k worth of Novartis AG ADR's common stock.
Check Novartis Ownership Details
Novartis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2024-09-30 | 2.3 M | |
| Cullen Capital Management, Llc | 2024-09-30 | 2.3 M | |
| Wells Fargo & Co | 2024-06-30 | 2.1 M | |
| Envestnet Asset Management Inc | 2024-09-30 | 2 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 1.9 M | |
| Blackrock Inc | 2024-06-30 | 1.9 M | |
| State Street Corp | 2024-06-30 | 1.8 M | |
| Northern Trust Corp | 2024-09-30 | 1.7 M | |
| Fisher Asset Management, Llc | 2024-09-30 | 1.7 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 14.8 M | |
| Dodge & Cox | 2024-09-30 | 12.2 M |
Novartis Historical Income Statement
Novartis Stock Against Markets
Novartis Corporate Directors
| Ton Buechner | Non-Executive Independent Director | Profile | |
| Frans Houten | Non-Executive Independent Director | Profile | |
| Nancy Andrews | Non-Executive Independent Director | Profile | |
| Elizabeth Doherty | Non-Executive Independent Director | Profile |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.